middle.news
EMA Paediatric Committee Endorses Cynata’s CYP-001 Trial Plan for aGvHD
8:48am on Wednesday 3rd of June, 2026 AEST
•
Biotechnology
Read Story
EMA Paediatric Committee Endorses Cynata’s CYP-001 Trial Plan for aGvHD
8:48am on Wednesday 3rd of June, 2026 AEST
Key Points
EMA PDCO grants Positive Opinion on CYP-001 paediatric plan
Phase 2/3 trial planned for children post adult Phase 3 study
Phase 2 adult trial results due mid-2026 underpin next steps
aGvHD remains a critical unmet need with limited treatment options
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cynata Therapeutics (ASX:CYP)
OPEN ARTICLE